^
Association details:
| Biomarker: | ATM overexpression |
|---|---|
| Cancer: | Endometrial Cancer |
| Drug: | Lynparza (olaparib) (PARP inhibitor) + KU-55933 (ATM kinase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Inhibition of ATM with KU-55933 Sensitizes Endometrial Cancer Cell Lines to Olaparib
Published date:
12/18/2023
Excerpt:
To assess the biological function of ATM in endometrial cancer cells, we utilized KU-55933, a specific inhibitor of ATM, to interfere with its expression. The sensitivity to KU-55933 of these six cell lines was examined by CCK8 assay to determine the dose for combination treatment (Figure S4)....These results demonstrate that Olaparib in combination with KU-55933 may be an effective treatment means for endometrial cancer with high-level ATM.
DOI:
https://doi.org/10.2147/OTT.S426923
